Lumos Pharma, Inc.
(NASDAQ : NLNK)

... ...
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.47%131.020.0%$2314.17m
BNGOBioNano Genomics, Inc. 18.50%9.800.0%$2016.46m
GILDGilead Sciences, Inc. -0.06%66.941.0%$649.72m
AMGNAmgen, Inc. 0.58%253.501.3%$564.60m
CRSPCRISPR Therapeutics AG 1.83%188.490.6%$487.99m
REGNRegeneron Pharmaceuticals, Inc. 0.43%537.782.7%$478.09m
ALXNAlexion Pharmaceuticals, Inc. 1.19%159.732.0%$470.59m
NVAXNovavax, Inc. 3.74%126.9892.9%$417.43m
ILMNIllumina, Inc. 0.34%406.253.5%$396.72m
SRPTSarepta Therapeutics, Inc. 1.36%98.2413.8%$364.79m
VRTXVertex Pharmaceuticals, Inc. -0.44%237.591.9%$361.85m
BIIBBiogen, Inc. -0.25%269.441.7%$321.90m
BNTXBioNTech SE 2.86%108.440.0%$298.33m
EXASEXACT Sciences Corp. 1.30%150.0019.6%$243.95m
PACBPacific Biosciences of California, Inc. 3.06%37.427.4%$228.17m

Company Profile

Lumos Pharma, Inc. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Austin, TX.